Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
Authors
Anita Ahmed Turk
Melvin and Bren Simon Cancer Center, Indianapolis, IN;
Anita Ahmed Turk , Paul R. Helft , Amikar Sehdev , Safi Shahda , Patrick J. Loehrer Sr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04046887
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 731)
DOI
10.1200/JCO.2023.41.4_suppl.731
Abstract #
731
Poster Bd #
L18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
First Author: Chao Yin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.
First Author: Zev A. Wainberg
Poster
2022 ASCO Annual Meeting
A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
First Author: Benjamin Leon Musher
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
First Author: John Davelaar